Venus MedTech

Executive Summary

Venus MedTech is a leading Chinese medical device company focused on minimally invasive solutions for structural heart disease, particularly transcatheter heart valve systems. Founded in 2009 and headquartered in Hangzhou, the company has developed a portfolio of innovative products including the VenusA-Valve for aortic stenosis and the VenusP-Valve for pulmonic valve disease. Venus MedTech is publicly traded and has established a strong presence in the domestic market, with ongoing efforts to expand internationally. The company's technology is recognized for its clinical efficacy and safety, positioning it as a key player in the rapidly growing transcatheter valve therapy market. Looking ahead, Venus MedTech is expected to benefit from the aging population and increasing adoption of minimally invasive procedures in China. The company continues to invest in R&D for next-generation devices and is pursuing regulatory approvals in new geographies. While competition remains intense, Venus MedTech's first-mover advantage in certain valve segments and its robust clinical data provide a solid foundation for growth. Key upcoming catalysts include potential NMPA approvals for product line extensions, clinical trial readouts for novel devices, and strategic partnerships to access overseas markets. Overall, Venus MedTech is well-positioned to capture value in the structural heart intervention space.

Upcoming Catalysts (preview)

• Q2 2026NMPA approval for VenusA-Plus (next-generation TAVR system)80% success
• Q3 2026Clinical trial results for VenusP-Valve in native RVOT (pediatric/adult)70% success
• Q4 2026International distribution partnership for VenusA-Valve in Southeast Asia60% success